Latigo's public offering adds to a significant uptick in large biotech IPOs, positioning the company to compete with Vertex and Lilly in the non-opioid, ion-channel-blocking pain drug market. The successful raise reflects renewed investor confidence in the sector.

Braveheart is one of five biotechnology firms pricing IPOs this week, collectively targeting over $1 billion from public investors. The wave of offerings signals a strong recovery in biotech capital markets.

The startup becomes the 12th drug company to raise at least $250 million in an IPO this year, nearly matching totals last seen during the sector's pandemic peak. Attovia is developing treatments for eczema and pruritus.

The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround for Moderna. The approval represents a significant expansion of mRNA vaccine applications beyond COVID-19.

FDA approval of Orzeyful mostly clears the way for entry into a multibillion-dollar market for drugs that boost orexin proteins. Wall Street analysts project significant commercial potential for this new class of sleep medications.

The accelerated clearance of tudriqev follows two earlier rejections and the support of an advisory panel that disputed FDA scientists' arguments. The approval marks a significant turnaround for Replimune after previous regulatory setbacks.

Alkeus brought to late-stage testing a Stargardt disease therapy that Vertex founder Josh Boger once called the most perfect drug he'd ever seen if it works. The acquisition reflects continued interest in rare disease ophthalmology assets.

Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to drugs widely used to prevent organ rejection. The financing supports development of this novel approach to immunosuppression.

China is solidifying its position as a major destination for clinical trials, with infrastructure and regulatory improvements attracting global sponsors. The country's expanding capacity represents a significant shift in the global trial landscape.

The companies discontinued their Phase III combination study based on disappointing interim results. The decision highlights the ongoing challenges in developing effective cancer combination therapies.